Eli Lilly | LLY - Ebit



Eli Lilly reported $7.02B in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
AbbVie USD 5.72B 69M Jun/2025
Abbott USD 2.07B 105M Jun/2025
ALKERMES USD 92.98M 79.19M Jun/2025
Amgen USD 2.26B 1.34B Jun/2025
AstraZeneca USD 3.51B 1.3B Jun/2025
Baxter International USD 272M 120M Jun/2025
Biogen USD 816.6M 233.8M Jun/2025
Bristol-Myers Squibb USD 2.26B 1.92B Jun/2025
Drreddys Laboratories INR 19.88B 1.86B Jun/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Gilead Sciences USD 2.7B 189M Jun/2025
GlaxoSmithKline GBP 2.07B 462M Jun/2025
Glaxosmithkline GBP 2.07B 237.99M Jun/2025
J&J USD 6.94B 443M Jun/2025
Medtronic USD 1.52B 969M Jul/2025
Merck USD 6.36B 149M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD -9190000000 13.87B Jun/2025
Novartis USD 4.82B 39M Jun/2025
Novo Nordisk 34.08B 4.71B Jun/2025
Perrigo USD 55.6M 91M Jun/2025
Pfizer USD 2.6B 3.33B Jun/2025
Prestige Brands USD 71.76M 29.14M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 608.6M Jun/2025
Roche Holding CHF 11.29B 2.68B Jun/2024
Sanofi EUR 1.51B 1.39B Jun/2025
Sanofi EUR 1.51B 704.8M Jun/2025
United Therapeutics USD 276.9M 105.9M Jun/2025
Zoetis USD 1.02B 106M Jun/2025